泰瑞沙-话题@MedSci

#泰瑞沙#

8篇内容 | 788人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1517464, encodeId=b8f7151e464ac, content=<a href='/topic/show?id=43f265061a0' target=_blank style='color:#2F92EE;'>#泰瑞沙#</a>, objectTitle=中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益, objectType=article, longId=301654, objectId=d9c830165485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c830165485, replyNumber=0, likeNumber=38, createdTime=2022-03-27, rootId=0, userName=LShY0906_98743847, userId=2caa11077853, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c830165485, moduleTitle=中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c830165485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517463, encodeId=353b151e463dc, content=<a href='/topic/show?id=43f265061a0' target=_blank style='color:#2F92EE;'>#泰瑞沙#</a>, objectTitle=泰瑞沙在早期EGFR突变肺癌辅助治疗中可降低82%脑部复发风险, objectType=article, longId=201192, objectId=608e2011928b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=608e2011928b, replyNumber=0, likeNumber=41, createdTime=2020-09-26, rootId=0, userName=LShY0906_98743847, userId=2caa11077853, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=608e2011928b, moduleTitle=泰瑞沙在早期EGFR突变肺癌辅助治疗中可降低82%脑部复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=608e2011928b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517462, encodeId=606e151e462e3, content=<a href='/topic/show?id=43f265061a0' target=_blank style='color:#2F92EE;'>#泰瑞沙#</a>, objectTitle=ASCO 2020：泰瑞沙在早中期NSCLC中的疗效将公布, objectType=article, longId=194646, objectId=99c1194646de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99c1194646de, replyNumber=0, likeNumber=40, createdTime=2020-05-25, rootId=0, userName=LShY0906_98743847, userId=2caa11077853, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99c1194646de, moduleTitle=ASCO 2020：泰瑞沙在早中期NSCLC中的疗效将公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99c1194646de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517461, encodeId=94ab151e46172, content=<a href='/topic/show?id=43f265061a0' target=_blank style='color:#2F92EE;'>#泰瑞沙#</a>, objectTitle=泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物, objectType=article, longId=180287, objectId=3dc318028eda, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc318028eda, replyNumber=0, likeNumber=33, createdTime=2019-10-01, rootId=0, userName=LShY0906_98743847, userId=2caa11077853, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc318028eda, moduleTitle=泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc318028eda)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517460, encodeId=1f32151e46031, content=<a href='/topic/show?id=43f265061a0' target=_blank style='color:#2F92EE;'>#泰瑞沙#</a>, objectTitle=CFDA批准上市泰瑞沙®（甲磺酸奥希替尼片）审评概述，用于非小细胞性肺癌(NSCLC)成人患者的治疗, objectType=article, longId=122001, objectId=be1312200102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be1312200102, replyNumber=0, likeNumber=31, createdTime=2017-12-03, rootId=0, userName=LShY0906_98743847, userId=2caa11077853, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be1312200102, moduleTitle=CFDA批准上市泰瑞沙®（甲磺酸奥希替尼片）审评概述，用于非小细胞性肺癌(NSCLC)成人患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be1312200102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517459, encodeId=5150151e45915, content=<a href='/topic/show?id=43f265061a0' target=_blank style='color:#2F92EE;'>#泰瑞沙#</a>, objectTitle=泰瑞沙亚洲区数据公布有望成为一线治疗, objectType=article, longId=120973, objectId=c54f1209e3b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c54f1209e3b8, replyNumber=0, likeNumber=43, createdTime=2017-11-23, rootId=0, userName=LShY0906_98743847, userId=2caa11077853, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c54f1209e3b8, moduleTitle=泰瑞沙亚洲区数据公布有望成为一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c54f1209e3b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517458, encodeId=549d151e45867, content=<a href='/topic/show?id=43f265061a0' target=_blank style='color:#2F92EE;'>#泰瑞沙#</a>, objectTitle=肺癌靶向药泰瑞沙专项金融分期项目受到热烈欢迎, objectType=article, longId=109001, objectId=b2751090012f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2751090012f, replyNumber=0, likeNumber=37, createdTime=2017-08-18, rootId=0, userName=LShY0906_98743847, userId=2caa11077853, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2751090012f, moduleTitle=肺癌靶向药泰瑞沙专项金融分期项目受到热烈欢迎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2751090012f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517457, encodeId=8ec3151e45794, content=<a href='/topic/show?id=43f265061a0' target=_blank style='color:#2F92EE;'>#泰瑞沙#</a>, objectTitle=重磅喜讯 | 第三代肺癌靶向药物泰瑞沙在中国获批, objectType=article, longId=93371, objectId=4a35933e1c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a35933e1c7, replyNumber=0, likeNumber=40, createdTime=2017-03-27, rootId=0, userName=LShY0906_98743847, userId=2caa11077853, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a35933e1c7, moduleTitle=重磅喜讯 | 第三代肺癌靶向药物泰瑞沙在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a35933e1c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

泰瑞沙

2020-05-29

LShY0906_98743847 (审核中...)

前往app查看评论内容

#泰瑞沙#

中国亚组数据正式揭晓：泰瑞沙®用于早期EGFR突变肺癌患者辅助治疗，进一步证实中国人群临床获益

2022-03-27

LShY0906_98743847 (审核中...)

前往app查看评论内容

#泰瑞沙#

泰瑞沙在早期EGFR突变肺癌辅助治疗中可降低82%脑部复发风险

2020-09-26

LShY0906_98743847 (审核中...)

前往app查看评论内容

#泰瑞沙#

ASCO 2020：泰瑞沙在早中期NSCLC中的疗效将公布

2020-05-25

LShY0906_98743847 (审核中...)

前往app查看评论内容

#泰瑞沙#

泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物

2019-10-01

LShY0906_98743847 (审核中...)

前往app查看评论内容

#泰瑞沙#

CFDA批准上市泰瑞沙®（甲磺酸奥希替尼片）审评概述，用于非小细胞性肺癌(NSCLC)成人患者的治疗

2017-12-03

LShY0906_98743847 (审核中...)

前往app查看评论内容

#泰瑞沙#

泰瑞沙亚洲区数据公布有望成为一线治疗

2017-11-23

LShY0906_98743847 (审核中...)

前往app查看评论内容

#泰瑞沙#

肺癌靶向药泰瑞沙专项金融分期项目受到热烈欢迎

2017-08-18

LShY0906_98743847 (审核中...)

前往app查看评论内容

#泰瑞沙#

重磅喜讯 | 第三代肺癌靶向药物泰瑞沙在中国获批

2017-03-27

科室
- - 订阅+
  - 更多科室
工具
服务